Charles Cliff Duncan - 03 Nov 2026 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Reporting relationship: Director
Issuer ticker: VNDA
Reported as of: 03 Nov 2026
Net transaction value: +$38,094
SEC form: 4
Accepted by SEC: 05 Nov 2026, 16:16:44 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Cliff Duncan

Filing notes and source

Key filing fact

Charles Cliff Duncan filed Form 4 for Vanda Pharmaceuticals Inc. (VNDA) on 05 Nov 2026.

Key facts

This page summarizes Charles Cliff Duncan's Form 4 filing for Vanda Pharmaceuticals Inc. (VNDA).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Nov 2026, 16:16.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: +$38,094.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002130896 Primary reporting owner

Duncan Charles Cliff

Relationship: Director
Address: 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON
Signature: /s/ Charles Cliff Duncan
Signature date: 05 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VNDA transaction

Common Stock

Purchase

Transaction value: $2,847
Shares: +750
Change %: +0.76%
Price: $3.80
Shares after: 99,451
Date: 03 Nov 2026
Ownership: Direct
Footnotes: F1

VNDA transaction

Common Stock

Purchase

Transaction value: $13,171
Shares: +3,447
Change %: +3.5%
Price: $3.82
Shares after: 102,898
Date: 04 Nov 2026
Ownership: Direct
Footnotes: F2

VNDA transaction

Common Stock

Purchase

Transaction value: $22,076
Shares: +5,803
Change %: +5.6%
Price: $3.80
Shares after: 108,701
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.71 to $3.8389 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote (1) to this Form 4.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.7799 to $3.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote (2) to this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.72 to $3.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote (3) to this Form 4.